Lifestance Health Group (LFST) 46th Annual William Blair Growth Stock Conference summary

Market overview and industry trends

• Outpatient mental health is a large, growing market with over 60 million Americans affected and a $50 billion TAM, driven by increased demand, better diagnosis, and reduced social stigma.

• Decades of under-investment have led to affordability challenges, but recent payer and employer pressure is improving reimbursement and access.

• The industry remains highly fragmented, with most clinicians in solo or small practices, but consolidation is accelerating.

• Patients face friction in finding care due to fragmentation, affordability, and difficulty evaluating quality.

• There is a shift from access-focused care to prioritizing quality and outcomes, with measurement-based approaches gaining traction.

Competitive positioning and service model

• Operates at significant scale with over 8,300 employed clinicians across 33 states, delivering nearly 9 million visits to 1 million patients annually.

• Utilizes a hybrid model: 70% of visits are virtual, 30% in-person at 575 centers, allowing flexibility for patient preferences.

• Offers a broad range of services, including therapy, psychiatry, neuropsych testing, and emerging treatments for depression like TMS and SPRAVATO.

• In-network with commercial payers for 90% of revenue, reducing affordability barriers and enabling rapid patient access (3–5 days for new patients).

• Industry-leading customer acquisition cost, spending less than 2% of revenue to attract new patients.

Financial performance and growth strategy

• Achieved 13% CAGR in clinician growth and 18% CAGR in revenue, with adjusted EBITDA margins doubling from 5.5% to 11% over three years.

• Guidance targets mid-teens adjusted EBITDA margins by 2028, with a path to 15–20% margins in the coming years.

• Strong balance sheet with low leverage (1.5x), positive free cash flow for three years, and capital deployment across organic growth, tuck-in acquisitions, and share buybacks.

• Nearly $100 million spent on share repurchases this year, alongside building 20–30 new centers and select acquisitions.

• Growth driven by new graduates attracted to support and experienced clinicians seeking W2 employment and benefits.